ADOPT data not major setback for Eliquis from BMS/Pfizer
This article was originally published in Scrip
Executive Summary
Eliquis (apixaban), Bristol-Myers Squibb/Pfizer's new oral direct Factor Xa inhibitor anticoagulant, has failed to show superiority to the standard of care low molecular weight heparin enoxaparin (Sanofi's Lovenox/Clexane) in preventing venous thromboembolism in a Phase III trial in patients with acute medical illness.
You may also be interested in...
Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.